22 Nov 2018

BTG - The BTG acquisition: Small fly, big ointment

BTG Hotels (Group) Co Ltd Shs -A- (600258:SHG) | 0 0 0.0%

- Dr Andy Smith
- 2 pages

Following our note on BTG’s interim results, the proposed £3.3bn all-cash acquisition by Boston Scientific was announced. Further, on 21 November, BTG and its partner Johnson & Johnson (J&J) failed to prevent the launch of generic competition to Zytiga (28% of BTG’s H1 revenue). We examine the potential impact of generic Zytiga on the transaction.

Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

BTG - The BTG acquisition: Small fly, big ointment

BTG Hotels (Group) Co Ltd Shs -A- (600258:SHG) | 0 0 0.0%

Published: 22 Nov 2018
Author: Dr Andy Smith
Pages: 2

Following our note on BTG’s interim results, the proposed £3.3bn all-cash acquisition by Boston Scientific was announced. Further, on 21 November, BTG and its partner Johnson & Johnson (J&J) failed to prevent the launch of generic competition to Zytiga (28% of BTG’s H1 revenue). We examine the potential impact of generic Zytiga on the transaction.